Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 613

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 3
Chunk 613
---
public information has been fully disclosed, widely disseminated
to the public and at least two full business days has passed after such material nonpublic information has been disclosed.

Code
of Business Conduct and Ethics

We
have a Code of Business Conduct and Ethics that applies to our directors, officers and employees, including our principal executive officer,
principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Business
Conduct and Ethics is publicly available on our website at http://www.indaptusrx.com. We intend to satisfy the disclosure requirement
under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics, as well as
Nasdaq’s requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website
at texhe address and location specified above. The information contained on our website is not incorporated by reference into this Annual
Report.

Insider
Trading Policy

We
have adopted an insider trading policy that governs the purchase, sale, and/or other transactions of our securities by our directors,
officers and certain other covered persons, and which is reasonably designed to promote compliance with applicable insider trading laws,
rules and regulations, and any listing standards applicable to us. A copy of our insider trading policy is filed as Exhibit 19.1 to this
Annual Report on Form 10-K. In addition, with regard to any trading in our own securities, it is our policy to comply with the federal
securities laws and the applicable exchange listing requirements.

Committees
of the Board

Our
Board has established four standing committees—Audit, Compensation, Nominating, and Science and Technology. Each of Audit, Compensation
and Nominating Committee operates under a written charter that has been approved by our Board.

The
members of each of the Board committees and committee Chairpersons are set forth in the following chart.

    Name
     
    Audit
     
    Compensation
     
    Nominating
     
    Science and
    Technology

    Mark J. Gilbert, M.D.

    X

    William B. Hayes
     
    Chairperson
     
    X

    Hila Karah
     
    X

    Chairperson

    Anthony J. Maddaluna

    Chairperson
     
    X
     
    X

    Robert E. Martell, M.D., Ph.D.
     
    X